Skip to main content
Rhett Schiffman, MD, Ophthalmology, Irvine, CA

RhettMeadSchiffmanMDMS MHSA

Ophthalmology Irvine, CA

Physician

Dr. Schiffman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Schiffman's full profile

Already have an account?

  • Office

    118 Med Surge # 1
    Irvine, CA 92697
    Phone+1 949-824-6211
    Fax+1 949-824-4015

Education & Training

  • Henry Ford Health/Henry Ford Hospital
    Henry Ford Health/Henry Ford HospitalResidency, Ophthalmology, 1993 - 1996
  • Henry Ford Health/Henry Ford Hospital
    Henry Ford Health/Henry Ford HospitalResidency, Internal Medicine, 1983 - 1986
  • Universidad Autonoma de Ciudad Juarez
    Universidad Autonoma de Ciudad JuarezClass of 1982

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2002 - 2025
  • MI State Medical License
    MI State Medical License 1984 - 2004
  • American Board of Internal Medicine Internal Medicine
  • American Board of Ophthalmology Ophthalmology

Awards, Honors, & Recognition

  • Fellow (FAAO) American Academy of Ophthalmology

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Phase 3 Presbyopia Drop Trial Launches
    Phase 3 Presbyopia Drop Trial LaunchesApril 6th, 2022
  • Visus Therapeutics Appoints Industry Leaders Tracy Valorie and Dwight Moxie to Board of Directors
    Visus Therapeutics Appoints Industry Leaders Tracy Valorie and Dwight Moxie to Board of DirectorsAugust 25th, 2021
  • Visus Therapeutics Expands Ophthalmic Drug Portfolio with Investigational Therapies for Glaucoma and Age-Related Macular Degeneration; Secures Exclusive License for Novel Ophthalmic Drug Delivery Technology
    Visus Therapeutics Expands Ophthalmic Drug Portfolio with Investigational Therapies for Glaucoma and Age-Related Macular Degeneration; Secures Exclusive License for Novel Ophthalmic Drug Delivery TechnologyAugust 19th, 2021
  • Join now to see all

Professional Memberships